Evidence map›Paper›PMID 32086387›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2020

AMP-Activated Protein Kinase Restricts Zika Virus Replication in Endothelial Cells by Potentiating Innate Antiviral Responses and Inhibiting Glycolysis.

Sneha Singh, Pawan Kumar Singh, Hamid Suhail, Vaithilingaraja Arumugaswami, Philip E Pellett, Shailendra Giri, Ashok Kumar

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sneha SinghDepartment of Ophthalmology, Visual, and Anatomical Sciences, Wayne State University, Detroit, MI 48201.
Pawan Kumar SinghDepartment of Ophthalmology, Visual, and Anatomical Sciences, Wayne State University, Detroit, MI 48201.ORCID 0000-0001-5517-1120
Hamid SuhailDepartment of Neurology, Henry Ford Health Systems, Detroit, MI 48202.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; and.
Philip E PellettDepartment of Biochemistry, Microbiology, and Immunology, Wayne State University, Detroit, MI 48201.
Shailendra GiriDepartment of Neurology, Henry Ford Health Systems, Detroit, MI 48202.ORCID 0000-0002-7123-829X
Ashok KumarDepartment of Ophthalmology, Visual, and Anatomical Sciences, Wayne State University, Detroit, MI 48201; akuma@med.wayne.edu.
Wayne State University · USHenry Ford Health System · USUniversity of California, Los Angeles · US

Funding

Targeting NAD metabolism to ameliorate bacterial endophthalmitisR01EY026964 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2017 to 2026
$3.7M
Mechanisms of Inflammation Resolution in Bacterial EndophthalmitisR01EY027381 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2017 to 2026
$3.3M
Role of ABCG1 in Zika virus induced chorioretinal atrophyR21AI135583 · NIAID · WAYNE STATE UNIVERSITY · PI KUMAR, ASHOK · 2018 to 2019
$424k
NEI NIH HHS R01 EY026964NEI NIH HHS R01 EY027381NIAID NIH HHS R21 AI135583
6 · The paper itself

Abstract

Viruses are known to perturb host cellular metabolism to enable their replication and spread. However, little is known about the interactions between Zika virus (ZIKV) infection and host metabolism. Using primary human retinal vascular endothelial cells and an established human endothelial cell line, we investigated the role of AMP-activated protein kinase (AMPK), a master regulator of energy metabolism, in response to ZIKV challenge. ZIKV infection caused a time-dependent reduction in the active phosphorylated state of AMPK and of its downstream target acetyl-CoA carboxylase. Pharmacological activation of AMPK using 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), metformin, and a specific AMPKα activator (GSK621) attenuated ZIKV replication. This activity was reversed by an AMPK inhibitor (compound C). Lentivirus-mediated knockdown of AMPK and the use of AMPKα

Indexed as

AMP-Activated Protein KinasesCell LineEndothelial CellsGlycolysisHumansHuman Umbilical Vein Endothelial CellsImmunity, InnateInflammation MediatorsSignal TransductionVirus ReplicationZika VirusZika Virus InfectionAMP-Activated Protein KinasesInflammation Mediators

Identifiers

PMID32086387
PMCPMC7310572
OpenAlexW3007037356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.